Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension

Clinical trial NCT04907227 · TERMINATED

Trial details

NCT number: NCT04907227
Sponsor: Merck Sharp & Dohme LLC
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Prostatic Neoplasms

Start date: 2020-09-23
Primary completion: 2022-08-03
Enrollment: 81

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.